Does Magnesium Taurine Cognition Randomized Trial work?

Updated August 2026

Quick Answer

Magnesium Taurine Cognition Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Additionally, the failure of numerous pharmacological and non-pharmacological single-domain interventions in AD underscores the limitations of targeting single-disease mechanisms or single risk factors.

Key Takeaways

  • 01Additionally, the failure of numerous pharmacological and non-pharmacological single-domain interventions in AD underscores the limitations of targeting single-disease mechanisms or single risk factors. [Bereczki Erika (2025)]
  • 02There is a clear need for strategies addressing multiple risk factors and biological pathways simultaneously, with early intervention in the ADRD continuum being crucial for an optimal preventive effect [,]. [Bereczki Erika (2025)]
  • 03The World Health Organization (WHO) guidelines for risk reduction of cognitive decline and dementia, which are based on the synthesis of findings from intervention trials, recommend, among others, physical activity, a healthy balanced diet, cognitive training, as well as management of hypertension, diabetes, and dyslipidemia, for reducing the risk of cognitive decline []. [Bereczki Erika (2025)]
  • 041 2 3 4 5 6 7 Healthy ageing, preservation of cognitive functioning, and preventing Alzheimer’s disease (AD) and related dementias (ADRD) is a global priority, as effective ADRD therapeutics are still not widely available. [Bereczki Erika (2025)]
The current Migaku evidence database contains 2 reusable source documents for Magnesium Taurine Cognition Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Additionally, the failure of numerous pharmacological and non-pharmacological single-domain interventions in AD underscores the limitations of targeting single-disease mechanisms or single risk factors. [Bereczki Erika (2025); evidence level 1] - There is a clear need for strategies addressing multiple risk factors and biological pathways simultaneously, with early intervention in the ADRD continuum being crucial for an optimal preventive effect [,]. [Bereczki Erika (2025); evidence level 1] - The World Health Organization (WHO) guidelines for risk reduction of cognitive decline and dementia, which are based on the synthesis of findings from intervention trials, recommend, among others, physical activity, a healthy balanced diet, cognitive training, as well as management of hypertension, diabetes, and dyslipidemia, for reducing the risk of cognitive decline []. [Bereczki Erika (2025); evidence level 1] - 1 2 3 4 5 6 7 Healthy ageing, preservation of cognitive functioning, and preventing Alzheimer’s disease (AD) and related dementias (ADRD) is a global priority, as effective ADRD therapeutics are still not widely available. [Bereczki Erika (2025); evidence level 1] - This case series presents outcomes of the first 51 patients who participated in one such program and aims to add to preliminary evidence regarding the efficacy of a personalized multimodal integrative functional medicine approach to cognitive decline in the context of prior uncontrolled and ongoing controlled trials. [Kogan Mikhail (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Risk reduction and precision prevention across the Alzheimer’s disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches
  2. The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series